The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.
Educational reference only. Nothing on this page constitutes medical advice or encourages personal use of this compound. Always consult a qualified healthcare provider before any decision involving your health.
For decades, the mitochondrial genome was thought to encode only 13 proteins. The discovery that it also encodes signaling peptides that circulate systemically and regulate whole-body physiology is one of the more surprising findings in recent molecular biology.
The mitochondrial genome is a small circular DNA molecule (16,569 base pairs in humans) that encodes 13 proteins (all components of the oxidative phosphorylation machinery), 22 transfer RNAs, and 2 ribosomal RNAs. This compact genome was considered fully mapped and understood. In 2001, Hashimoto et al. (Science) discovered Humanin while screening for genes that could protect neurons from Alzheimer's disease-related amyloid toxicity — they traced the protective sequence to a small open reading frame within the 16S rRNA region of the mitochondrial genome. This was unexpected: a ribosomal RNA gene was encoding a bioactive signaling peptide.
In 2015, Lee et al. (Cell Metabolism) discovered MOTS-c in the 12S rRNA region using computational prediction of small open reading frames. MOTS-c activation of AMPK, its systemic metabolic effects, and its exercise-mimetic properties established it as a new class of regulatory peptide. Together, Humanin and MOTS-c founded the mitochondrial-derived peptide (MDP) class. Several others have been identified since (SHLP1-6, SHMOOSE) with overlapping and distinct functions. The field is less than 25 years old, most evidence is animal models, and the human clinical application is at an early stage.
THE CENTRAL TENSION
MOTS-c and Humanin represent a genuinely new category of biology — the mitochondrial genome encoding systemic regulatory signals beyond energy production. The pharmacological case for their combination is clean: MOTS-c targets metabolic regulation (AMPK, folate/methionine cycle, glucose uptake, exercise response); Humanin targets cellular survival (anti-apoptotic, neuroprotective, anti-inflammatory). These are non-overlapping mechanisms addressing complementary hallmarks of aging. Both decline with age. Both have animal evidence for the benefits they are claimed to produce. Both have essentially no human RCT evidence for their use as injectable peptides in community protocols. The stack sits at the intersection of genuinely interesting biology and essentially unvalidated community application.
Both peptides have documented age-related plasma level declines in humans, which provides the restoration framing for their community use. MOTS-c: plasma concentrations significantly lower in older vs younger adults; exercise-induced MOTS-c rise is attenuated in older individuals; aging impairs the mitochondria-to-nucleus MOTS-c translocation that drives metabolic adaptation. Humanin: approximately 50% decline per decade after age 40 documented in human plasma studies; this decline is associated with increased Alzheimer's risk, cardiovascular risk, and reduced stress resistance in longitudinal analyses. The restoration framing: exogenous MOTS-c and Humanin administration replenishes peptides that mitochondria are producing less of with age — analogous to GHK-Cu's restoration framing (plasma GHK levels declining 200 → 80 ng/mL with age). Both peptides are endogenous; their supplementation is framed as age-related restoration rather than supraphysiological enhancement.
Feature
MOTS-c
Humanin
Full name
Mitochondrial ORF of the 12S rRNA type-c
Humanin (HN; no longer an acronym)
Discovery
Lee et al. (2015, Cell Metabolism); 12S rRNA smORF
Hashimoto et al. (2001, Science); 16S rRNA smORF
Structure
21 amino acids; Thr-Met-Lys-Thr-Ile-Ile-Thr-Pro-Gly-Glu-Ile-Asn-Leu-Lys-Ala-Ala-Arg-Arg-Ser-Asp-Ile
21 amino acids; Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys
Receptor/target
AMPK (via folate/methionine cycle AICAR accumulation); no specific GPCR identified; nuclear translocation under stress
FPRL1 (formyl peptide receptor-like 1) on neurons/immune cells; JAK2/STAT3 signaling; IGFBP-3 binding (displaces IGF-1)
Primary mechanism
AMPK activation → glucose uptake (GLUT4), fatty acid oxidation, mitochondrial biogenesis, anti-inflammatory (via AMPK); folate cycle perturbation generates AICAR → AMPK
Anti-apoptotic (JAK2/STAT3; Bcl-2 upregulation; prevents cyt-c release); neuroprotection (blocks Aβ 25-35 neuronal death); anti-inflammatory; IGFBP-3 displacement → free IGF-1 ↑
Age-related decline
Yes — plasma MOTS-c significantly lower in older adults; exercise-induced rise attenuated with aging
Yes — plasma Humanin declines ~50% per decade after age 40; linked to Alzheimer's risk in studies
Human evidence
Phase 2 trial (NCT04483128; postmenopausal women; insulin resistance); muscle metabolism human studies
No human RCT; observational correlation with Alzheimer's risk; human plasma level studies
Community dose
5-10 mg SubQ per injection; 3-5x/week
Mcg range; intranasal (primary) or SubQ; 50-250 mcg per dose
Vendor
Limitless (combination blend); individual vials also available
Limitless (combination blend); individual vials also available
The MOTS-c + Humanin combination is pharmacologically coherent because the two peptides target completely different cellular stress pathways. They do not compete; they complement.
MOTS-c's primary function is metabolic regulation via AMPK. The mechanism: MOTS-c travels from mitochondria to the cytoplasm and nucleus under metabolic stress. In the nucleus, it interacts with the folate cycle — disrupting the folate cycle leads to accumulation of AICAR (5-aminoimidazole-4-carboxamide ribonucleotide), a known endogenous AMPK activator. AMPK activation drives: glucose transporter (GLUT4) translocation to the cell membrane (increased glucose uptake); fatty acid oxidation upregulation; mitochondrial biogenesis (via PGC-1α); inhibition of anabolic mTOR pathway (reducing excess protein synthesis at the cost of catabolic stress resistance); systemic anti-inflammatory effects (AMPK suppresses NF-kB in immune cells). This AMPK-mediated metabolic reprogramming is why MOTS-c is described as an 'exercise mimetic' — it activates the same molecular switches that exercise turns on.
Humanin operates through a completely different pathway: cell survival signaling. It binds the FPRL1 receptor (formyl peptide receptor-like 1) on neurons and immune cells, triggering JAK2/STAT3 signaling that upregulates anti-apoptotic proteins (Bcl-2, Bcl-xL) and prevents cytochrome c release from mitochondria. This anti-apoptotic activity is the mechanism through which Humanin protects neurons from amyloid-beta toxicity in Alzheimer's disease models — blocking the mitochondrial apoptotic pathway that Aβ25-35 triggers in neurons. Additionally, Humanin binds IGFBP-3 (insulin-like growth factor binding protein 3), displacing IGF-1 from IGFBP-3 and increasing free IGF-1 availability in tissues. The anti-inflammatory mechanism (cytokine suppression) adds a systemic protective dimension.
The two mechanisms are genuinely non-overlapping: MOTS-c (AMPK/metabolic regulation, exercise mimicry, glucose and fat metabolism, mitochondrial biogenesis) and Humanin (anti-apoptotic, neuroprotective, IGFBP-3/IGF-1 modulation, cytoprotection). Together they address: energy metabolism and metabolic health (MOTS-c), plus cellular survival and neuroprotection (Humanin). In aging biology terms: MOTS-c addresses metabolic hallmarks of aging (declining metabolic flexibility, insulin resistance, mitochondrial dysfunction); Humanin addresses cellular survival hallmarks (increased apoptosis, neurodegeneration susceptibility, IGF axis dysregulation).
Aging Hallmark
MOTS-c Coverage
Humanin Coverage
Mitochondrial dysfunction
Yes — AMPK → mitochondrial biogenesis via PGC-1α
Partial — prevents mitochondrial apoptotic pathway activation
Metabolic dysregulation
Yes — primary mechanism: GLUT4, fat oxidation, insulin sensitivity
Partial — IGFBP-3 displacement increases free IGF-1
Cellular apoptosis/death
Indirect (AMPK anti-inflammatory)
Yes — primary mechanism: JAK2/STAT3 anti-apoptotic
Neurodegeneration
None specific
Yes — Aβ toxicity protection; plasma Humanin inversely correlated with Alzheimer's risk
Chronic inflammation
Yes — AMPK → NF-kB suppression
Yes — cytokine suppression via FPRL1/STAT3
Exercise response/adaptation
Yes — exercise mimetic; amplifies exercise benefits
None specific
The most significant human data: NCT04483128 (Phase 2; postmenopausal insulin-resistant women; MOTS-c 2mg or 4mg SubQ for 12 weeks); results showed improvements in insulin sensitivity (HOMA-IR) and metabolic biomarkers. Lee et al. (2015, Cell Metabolism): foundational discovery paper; MOTS-c injections in obese mice on high-fat diet reversed obesity-induced insulin resistance; sedentary mice given MOTS-c showed metabolic improvements equivalent to exercise. Kim et al. (2018, Cell Metabolism): exercise increases plasma MOTS-c; MOTS-c mediates some of exercise's adaptive benefits; translocation of MOTS-c from mitochondria to nucleus during metabolic stress. Grade B (limited human; one Phase 2 trial in specific population) for the metabolic indication; Grade C (animal) for general metabolic and longevity effects.
No human RCT for injectable Humanin use exists. Human observational evidence: plasma Humanin levels are significantly lower in Alzheimer's disease patients vs age-matched controls; Humanin levels correlate inversely with Alzheimer's risk scores in human cohorts. Plasma Humanin declines approximately 50% per decade after age 40 in human studies. Hashimoto et al. (2001, Science): foundational discovery; Humanin protects neurons from amyloid-beta 25-35 toxicity in cell culture and in vivo neuronal models; the strongest and most replicated finding. Grade C (animal/in vitro) for neuroprotective and anti-apoptotic effects; Grade D (observational correlation) for Alzheimer's connection in humans.
Zero published studies have evaluated MOTS-c + Humanin in combination. No preclinical combination study exists. The combination rationale is mechanistic extrapolation. The stackGrade C reflects individual component animal evidence, not combination data.
Limitless combination blend: available as a pre-mixed vial. Community use typically pairs MOTS-c (higher mg doses, SubQ) with Humanin (lower mcg doses, intranasal primary or SubQ). The dose mismatch (mg for MOTS-c vs mcg for Humanin) reflects their different potency profiles at receptor level. Standard community approaches: MOTS-c 5-10 mg SubQ 3-5x/week; Humanin 50-200 mcg intranasal (preferred for CNS access via olfactory pathway) or SubQ. Cycle: 4-8 weeks on; 4+ weeks off; no established washout pharmacokinetics for either peptide in humans. Timing: MOTS-c before training (exercise synergy); Humanin timing less critical but morning preferred. Storage: refrigerate; light-sensitive.
Lee C, Zeng J, Drew BG, et al. (2015). The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance. Cell Metabolism. 21(3):443-454. [Foundational MOTS-c discovery and metabolic effects; AMPK activation; exercise mimetic; obesity reversal in mouse models.]
Kim KH, Son JM, Benayoun BA, Lee C. (2018). The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metabolism. 28(3):516-524. [MOTS-c nuclear translocation; gene expression regulation; exercise-induced MOTS-c; mechanism detail.]
NCT04483128. (Phase 2; postmenopausal women; insulin resistance; MOTS-c 2mg and 4mg SubQ). [Most significant human MOTS-c trial; insulin sensitivity improvement; primary human evidence for metabolic indication.]
Hashimoto Y, et al. (2001). A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Aβ. Science. 293(5530):714-718. [Humanin foundational discovery; neuronal protection from amyloid-beta 25-35 toxicity; cloned from Alzheimer's brain library; the paper that launched the Humanin field.]
Muzumdar RH, et al. (2009). Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice. Arterioscler Thromb Vasc Biol. [Humanin cardioprotective effects; STAT3 pathway; anti-apoptotic in cardiac ischemia models.]
Cobb LJ, et al. (2016). Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Aging (Albany NY). 8(4):796-809. [Age-related decline data for both MOTS-c and Humanin in humans; plasma correlation studies; aging pattern documented.]
MOTS-c + Humanin is the longevity peptide stack with the most interesting theoretical framework in the book. It is also the one with the least human evidence for the specific community protocol.
The combination story: two peptides from the mitochondrial genome that were only discovered in the 2000s and 2010s, both declining with age, addressing non-overlapping aging hallmarks (metabolic decline and cellular survival respectively), combined in a stack that Limitless sells and the community uses for longevity and metabolic health. The biology is genuinely fascinating. The human evidence for MOTS-c as an injectable peptide is one Phase 2 trial in a specific population. The human evidence for injectable Humanin is zero RCTs. The combination evidence is zero studies. The mechanistic case for the combination is coherent. Whether it works in community protocols at community doses is unknown.
STACK SUMMARY
MOTS-c + Humanin Blend: type=stack; slug=motsc-humanin-stack; stackGrade=C. COMPONENTS: mots-c + humanin. Limitless sells as specific blend. relatedStacks: none defined. indication: longevity/anti-aging; metabolic health; neuroprotection; mitochondrial function. COMPOUND CLASS: Mitochondrial-Derived Peptides (MDPs) — encoded by small open reading frames (smORFs) in mitochondrial DNA. Both 21-amino acid peptides. MOTS-c: 12S rRNA smORF; discovered Lee 2015 (Cell Metabolism). Humanin: 16S rRNA smORF; discovered Hashimoto 2001 (Science). MOTS-c MECHANISM: AMPK activation via folate/methionine cycle AICAR generation; nuclear translocation under metabolic stress; GLUT4 translocation; fatty acid oxidation; mitochondrial biogenesis (PGC-1α); exercise mimetic; NF-kB anti-inflammatory. Decline: plasma MOTS-c significantly lower in older adults; exercise-induced rise attenuated. HUMANIN MECHANISM: FPRL1 receptor → JAK2/STAT3 anti-apoptotic signaling; Bcl-2/Bcl-xL upregulation; prevents cyt-c release; blocks Aβ25-35 neuronal toxicity; IGFBP-3 displacement → free IGF-1 ↑; anti-inflammatory. Decline: ~50% per decade after age 40 (Cobb 2016). COMBINATION RATIONALE: non-overlapping mechanisms (metabolic/AMPK vs cytoprotective/anti-apoptotic); complementary aging hallmarks addressed simultaneously; no overlap, no redundancy. EVIDENCE: MOTS-c = B (Phase 2 NCT04483128; postmenopausal insulin-resistant women; insulin sensitivity improved) + C (Lee 2015; mouse obesity/IR reversal; Kim 2018; exercise synergy). Humanin = C (Hashimoto 2001; Aβ neuroprotection) + D (human observational plasma correlation with Alzheimer's risk). Combination = E (zero studies). AGE DECLINE: both peptides documented to decline with age in human plasma → restoration framing. COMMUNITY: MOTS-c 5-10 mg SubQ 3-5x/week; Humanin 50-200 mcg intranasal or SubQ; 4-8 week cycles. STORAGE: refrigerate; light-sensitive. COMPANION CHAPTERS: pbmotscv4 (MOTS-c); pbhumaninv4 (Humanin).
— End of MOTS-c + Humanin Blend —
THE PEPTIDE BIBLE | MOTS-c + Humanin Blend | For Research & Educational Purposes Only
A Structural Modification of Semax With No Published Studies of Its Own. Being Sold as 'The Most Potent Semax Analog.' Every Claim Belongs to Its Parent Compound.
The Compound That Raises NAD+ By Stopping the Body From Destroying It. NNMT: The Enzyme That Wastes Nicotinamide. Fat Loss Without Food Restriction in Mice. The Neelakantan Group's Research Tool Repurposed as a Longevity Drug. Zero Human Trials. 100 mg/Day Community Dose Extrapolated From Mouse IP Injections. The 1-MNA Question: The Metabolite You're Blocking Has Protective Roles in Liver and Kidney. A 2025 Cell/TPS Review Calls for Clinical Translation. Clinics Already Prescribing It Without FDA Ruling on Safety.
Six Human Clinical Trials. 900+ Participants. Safety Indistinguishable From Placebo. Primary Fat Loss Endpoint Failed. WADA Banned. FDA Rejected for Compounding. The Community Uses It Anyway at Doses That Never Worked in the Trials.